Biologically Active Small Molecules

An &omega-6 isomer of docosapentaenoic acid formed by the elongation and desaturation of arachidonic acid diminished during fatty acid desaturase syndrome and increased in nonalcoholic steatohepatitis.

An &omega-6 isomer of docosapentaenoic acid formed by the elongation and desaturation of arachidonic acid diminished during fatty acid desaturase syndrome and increased in nonalcoholic steatohepatitis.

A natural retinoid that associates with CRBP-I and CRBP-II (Kds = 50 and 90 nM, respectively), which are involved in the intracellular transport of retinol an intermediate of the phototransduction pathway of photoreceptors can form toxic

A natural retinoid that associates with CRBP-I and CRBP-II (Kds = 50 and 90 nM, respectively), which are involved in the intracellular transport of retinol an intermediate of the phototransduction pathway of photoreceptors can form toxic

A natural retinoid that associates with CRBP-I and CRBP-II (Kds = 50 and 90 nM, respectively), which are involved in the intracellular transport of retinol an intermediate of the phototransduction pathway of photoreceptors can form toxic

A natural retinoid that associates with CRBP-I and CRBP-II (Kds = 50 and 90 nM, respectively), which are involved in the intracellular transport of retinol an intermediate of the phototransduction pathway of photoreceptors can form toxic

A SMO antagonist that inhibits both wild-type (IC₅₀ = 50 nM) and mutant SMO, including the D473H SMO mutant (IC₅₀s = 300-1000 nM).

A SMO antagonist that inhibits both wild-type (IC₅₀ = 50 nM) and mutant SMO, including the D473H SMO mutant (IC₅₀s = 300-1000 nM).

A SMO antagonist that inhibits both wild-type (IC₅₀ = 50 nM) and mutant SMO, including the D473H SMO mutant (IC₅₀s = 300-1000 nM).

A SMO antagonist that inhibits both wild-type (IC₅₀ = 50 nM) and mutant SMO, including the D473H SMO mutant (IC₅₀s = 300-1000 nM).

An isomer of hypoxanthine that inhibits xanthine oxidoreductase (IC50 values between 0.2 and 50 &muM) lowers serum and urinary uric acid levels in vivo and is used to treat gout and hyperuricemia.

An isomer of hypoxanthine that inhibits xanthine oxidoreductase (IC50 values between 0.2 and 50 &muM) lowers serum and urinary uric acid levels in vivo and is used to treat gout and hyperuricemia.